- Fee assured
- Verified this account
Dr Edward Nash is a consultant physician at Birmingham Heartlands Hospital and Honorary Senior Clinical Lecturer in the School of Clinical and Experimental Medicine at the University of Birmingham Medical School. He trained in respiratory medicine in Bristol and spent 12 months as CF fellow in Toronto, Canada at the largest CF clinic in North America. As part of this fellowship he also worked as Lung Transplant fellow in the busiest transplant unit in North America.
Currently he cares for patients with general respiratory conditions and his specialist interest is CF. He works as one of the four consultant physicians in a large multidisciplinary team at the West Midlands Adult CF Centre at Birmingham Heartlands Hospital. He also provides the endobronchial ultrasound (EBUS) service at Heartlands Hospital and is clinical lead for bronchoscopy and pleural disease. He wrote the Trust guidelines for community acquired pneumonia, pleural effusion and chest drain insertion. He helped to establish a ward-based physician-led pleural ultrasound service to improve the safety and timeliness of pleural procedures for inpatients with pleural effusions in the hospital. He regularly trains junior doctors in chest drain insertion and leads the regional respiratory SpR training days in bronchoscopy and CF.
Areas of interest
Lung cancer; Chronic obstructive pulmonary disease (COPD); Pulmonary fibrosis; Bronchiectasis; Asthma; Pleural disease; Cough
Current NHS consultant posts held
Consultant Physician, Birmingham Heartlands Hospital and Honorary Senior Clinical Lecturer in the School of Clinical and Experimental Medicine at the University of Birmingham Medical School.
Dr Nash's research interests include clinical research in a variety areas related to adults with CF.
Golf, Victorian British watercolours, Family.
Clinical excellence award level 4.
Most recent publications are:
1: Hoo ZH, Coates E, Maguire C, Cantrill H, Shafi N, Nash EF, McGowan A, Bourke
SJ, Flight WG, Daniels TV, Nightingale JA, Allenby MI, Curley R, Wildman MJ. Pragmatic criteria to define chronic pseudomonas aeruginosa infection among adults with cystic fibrosis. Eur J Clin Microbiol Infect Dis. 2018 Nov;37(11):2219-2222.
2: Barr HL, Halliday N, Barrett DA, Williams P, Forrester DL, Peckham D, Williams
K, Smyth AR, Honeybourne D, Whitehouse JL, Nash EF, Dewar J, Clayton A, Knox AJ,
Cámara M, Fogarty AW. Diagnostic and prognostic significance of systemic alkyl quinolones for P. aeruginosa in cystic fibrosis: A longitudinal study; response to comments. J Cyst Fibros. 2017 Nov;16(6):e21.
3: Khan AA, Nash EF, Whitehouse J, Rashid R. Improving the care of patients with
cystic fibrosis (CF). BMJ Open Qual. 2017 Sep 4;6(2).
4: Rowbotham NJ, Smith S, Leighton PA, Rayner OC, Gathercole K, Elliott ZC, Nash
EF, Daniels T, Duff AJA, Collins S, Chandran S, Peaple U, Hurley MN, Brownlee K,
Smyth AR. The top 10 research priorities in cystic fibrosis developed by a partnership between people with CF and healthcare providers. Thorax. 2018
5: Greenwood J, Schwarz C, Sommerwerck U, Nash EF, Tamm M, Cao W, Mastoridis P,
Debonnett L, Hamed K. Ease of use of tobramycin inhalation powder compared with
nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection. Ther Adv Respir Dis. 2017 Jul;11(7):249-260.
6: Choyce J, Shaw KL, Sitch AJ, Mistry H, Whitehouse JL, Nash EF. A prospective
pilot study of home monitoring in adults with cystic fibrosis (HOME-CF): protocol for a randomised controlled trial. BMC Pulm Med. 2017 Jan 23;17(1):22.
Courses offered to GPs
Talks focusing on the management of patients with COPD, asthma, pleural disease, CF and bronchiectasis.
Reference number 4543141
Post treatment communication
Following treatment of a Bupa member, I will communicate with GPs in line with Department of Health, GMC and appropriate professional bodies guidelines.